Preprint says standard DNA-synthesis screeners pass many AI-redesigned pathogen proteins
bioRxiv · Research preprint
Read the source (opens in a new tab)- What happened
- Two Yale School of Medicine researchers, G. Oualline and M. Noon, posted a bioRxiv preprint on October 20, 2026 testing whether widely used DNA-synthesis screening software catches AI-redesigned versions of known pathogenic proteins.
- Key points
- On their test sets the alignment-based screeners IBBIS commec and SeqScreen passed 18.5% and 44.7% of the AI-redesigned, "putatively functional" pathogenic protein variants the authors generated.
- Most screening software relies on sequence alignment, which the authors say is vulnerable to AI redesign, and software-only screening also requires trusting the machine's operator.
- They propose Capiti, an offline screener that listens to a synthesizer's "valve control signals" and aborts a run on detecting "incipient pathogenic function," recognizing protein fold rather than sequence.
- Capiti passed 0.24% of the same variants in their tests; they release two models, Capiti-E and Capiti-C, and a synthesizer emulator called emusynth.
- Evidence
- A preprint, not peer reviewed, by two Yale School of Medicine authors, who say they did the work in their individual capacities, not as part of their Yale duties. The figures come from the authors' own test sets of computationally generated protein variants, not wet-lab confirmation of function.
- Uncertain
- The variants are software designs the authors call "putatively functional"; the abstract reports no laboratory confirmation that they would be toxic, and the preprint has not been peer reviewed.